-
Publication Venue For
-
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge..
30:243-249.
2019
-
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer..
29:2068-2075.
2018
-
ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia..
28:1949-1956.
2017
-
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study..
27:1940-1946.
2016
-
Corrigendum to Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram [Ann Oncol 26, (2015) 1930-1935] doi: 10.1093/annonc/mdv279.
27:753.
2016
-
Reply to the letter to the editor 'Integration between oncology and palliative care: does one size fit all?' by Verna et al..
27:549-550.
2016
-
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doi: 10.1093/annonc/mdv310.
26:2507-2508.
2015
-
Indicators of integration of oncology and palliative care programs: an international consensus..
26:1953-1959.
2015
-
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†..
26:894-901.
2015
-
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer..
26:762-768.
2015
-
Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO)..
25:1558-1562.
2014
-
RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
25:1670-1671.
2014
-
Attitudes of patients with metastatic breast cancer toward research biopsies..
24:1853-1859.
2013
-
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'..
18 Suppl 10:x1-x2.
2007
-
Treatment options in renal cell carcinoma: past, present and future..
18 Suppl 10:x25-x31.
2007
-
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma..
18:1216-1223.
2007
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804..
18:1071-1079.
2007
-
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902..
18:331-337.
2007
-
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials..
17:1749-1760.
2006
-
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference..
17:1615-1619.
2006
-
Molecular imaging in oncology..
17 Suppl 10:x287-x292.
2006
-
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer..
17:986-989.
2006
-
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer..
16:1458-1462.
2005
-
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors..
16:1391-1397.
2005
-
Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group..
16:972-980.
2005
-
An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)..
16:825-833.
2005
-
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials..
16:558-565.
2005
-
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer..
16:579-584.
2005
-
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study..
15:1173-1178.
2004
-
Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity..
15:1033-1041.
2004
-
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate..
15:974-978.
2004
-
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC..
15:410-418.
2004
-
Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about?.
14:1312-1325.
2003
-
Cancer mortality trends in the EU and acceding countries up to 2015..
14:1148-1152.
2003
-
Cancer mortality in Ireland, 1926-1995..
14:323-332.
2003
-
Pegfilgrastim: the promise of pegylation fulfilled..
14:6-7.
2003
-
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study..
13:1576-1582.
2002
-
Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay..
13:895-902.
2002
-
A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer..
13:435-440.
2002
-
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients..
13:258-266.
2002
-
Very young women (<35 years) with operable breast cancer: features of disease at presentation..
13:273-279.
2002
-
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels..
13:73-80.
2002
-
Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study..
13:95-102.
2002
-
Evaluation and appraisal of randomized controlled trials in myeloma..
12:1611-1617.
2001
-
Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma..
12:643-646.
2001
-
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study..
12:633-641.
2001
-
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study..
12:535-540.
2001
-
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies..
11:1313-1322.
2000
-
Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B..
11:1141-1146.
2000
-
A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL..
11:691-695.
2000
-
Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer..
11:229-230.
2000
-
Phase I study of Doxil and vinorelbine in metastatic breast cancer..
10:1113-1116.
1999
-
Recent advances in the treatment of prostate cancer..
10:891-898.
1999
-
A comprehensive assessment of satisfaction with care: preliminary psychometric analysis in an oncology institute in Italy..
10:839-846.
1999
-
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234..
10:597-600.
1999
-
Assessment of response in primary chemotherapy for breast cancer..
9:1140-1141.
1998
-
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors..
9:1003-1008.
1998
-
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B..
9:297-306.
1998
-
Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan..
9:213-216.
1998
-
The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy..
8:1117-1124.
1997
-
Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody..
8:919.
1997
-
One and a half decades of the Lugano International Conference on Malignant Lymphoma: variations on a theme or true progress?.
8 Suppl 1:1-3.
1997
-
The sixth Lugano conference: Basic science papers.
8.
1997
-
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia..
6:300-301.
1995
-
Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma..
5:468-470.
1994
-
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma..
5:286-287.
1994
-
Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B..
3:727-732.
1992
-
Original article: Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the cancer and leukemia group B.
3:727-732.
1992
-
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin..
2:519-520.
1991
-
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data..
2 Suppl 1:47-50.
1991
-
A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients
2018
-
An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T plus E) in non-small cell lung cancer (NSCLC)
2018
-
Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone plus /- bevacizumab (B)
2018
-
Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER21 gastric adenocarcinoma (GEA)
2018
-
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1 degrees) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)
2018
-
Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial
2018
-
EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naive prostate cancer (HSPC)
2018
-
NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)
2018
-
Novel small-molecule RORc agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial
2018
-
QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset
2018
-
Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies
2018
-
ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress
2018
-
Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)
2018
-
Variability of current global practice patterns in the management of metastatic colorectal cancer
2018
-
A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival
2017
-
KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC)
2017
-
Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
2017
-
Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
2017
-
Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
2017
-
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
2017
-
QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
2017
-
Impact of the sterol 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol on tumor-pathological features, prognosis and response to statin treatment in breast cancer
2017
-
Comparison of chemoradiotherapy treatment strategies in stage III non-small cell lung cancer among elderly patients from multiple data sources
2017
-
A randomized phase II study of leucovorin, 5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively-resected, node-positive esophageal squamous cell carcinoma
2016
-
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial
2016
-
First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
2016
-
Impact of chemotherapy-induced nausea and vomiting (CINV) on emergency department (ED) visits and disruption of chemotherapy: results of a survey of oncology nurses
2016
-
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
2016
-
Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
2016
-
Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
2015
-
ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI)
2012
-
ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
2012
-
OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
2012
-
SURVIVAL AMONG METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A RANDOMIZED CONTROLLED TRIAL (RCT) VS AN OBSERVATIONAL COHORT STUDY (OCS)
2012
-
TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL
2012
-
PATIENT PREFERENCES FOR REDUCING TOXICITIES OF TREATMENTS FOR GASTROINTESTINAL STROMAL TUMOR (GIST): A CONJOINT ANALYSIS STUDY
2010
-
PATIENT PREFERENCES FOR TARGETED AGENTS IN RENAL CELL CARCINOMA (RCC): A BENEFIT RISK CONJOINT STUDY
2010
-
FOUR POLYMORPHISMS IN CYTOCHROME P450 1B1 (CYP1B1) GENE AND BREAST CANCER RISK: A META-ANALYSIS
2010
-
A pilot study of myeloablative (MA) autologous stem cell (AutoSCT) followed by reduced intensity allogeneic transplantation (RI AlloSCT) in children with poor risk Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL)
2008
-
Ovarian ablation or ovarian suppression versus chemotherapy for hormone receptor positive operable breast cancer: A meta-analysis
2007
-
Trastuzumab with adjuvant chemotherapy for resectable breast cancer: A meta-analysis
2007
-
Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC)
2006
-
Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307
2006
-
Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633
2004
-
Immunotherapy of cancer with dendritic cell-based tumor vaccines
1998
-
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data
1991